A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

NCT06968845

Status	RECRUITING
Phase	Phase 2
Sponsor	Rein Therapeutics
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (8)

- Male or female age 40 years or older.
- Willing and able to provide written informed consent.
- Diagnosis of IPF within 5 years of Screening as confirmed by a centrally read HRCT of the chest as defined by the ATS/ERS/JRS/ALAT guideline. HRCT lung fibrosis by central read during screening must involve e 10% of the lung and be greater than emphysema involvement of the lung.
- Forced vital capacity (FVC) percent predicted e 45% at Screening.
- Diffusion capacity of the lungs for carbon monoxide (DLCO), hemoglobin-corrected percent predicted e 30% within 8 weeks prior to Randomization.

... and 3 more (see full listing online)

Exclusion (15)

- Forced expiratory volume in 1 second (FEV1)/FVC \< 0.7 at Screening.
- Use of N-acetyl cysteine or other supplements including but not limited to quercetin, omega-3 fatty acids, dehydroepiandrosterone, polyphenols, and phytochemicals within 7 days prior to Randomization and through Week 24.
- Use of systemic corticosteroids at doses \> 10 mg/day of prednisone or equivalent within 28 days prior to Randomization.
- Active smoker.
- Pulmonary exacerbation within 3 months prior to Screening.

... and 10 more (see full listing online)

Locations (7 total)

UAB Lung Health Center, Birmingham, Alabama, United States
Paradigm Clinical Research Centers, LLC, San Diego, California, United States
Henry Ford Health, Detroit, Michigan, United States
... and 4 more locations